Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aura Biosciences successfully closed an underwritten public offering, raising approximately $299.4 million in gross proceeds to fund the development of its precision therapies for solid tumors, including its lead candidate bel-sar (AU-011). The offering included the sale of over 46 million shares of common stock plus pre-funded warrants, reflecting…